CTS trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CTS achieves its forward estimates and maintains a stable P/E multiple of 27.6x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, CTS Corporation (CTS) has a Wall Street consensus price target of N/A, based on estimates from 4 covering analysts. The company has a market capitalization of $1.92B.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CTS trades at a trailing P/E of 30.6x and forward P/E of 27.6x. The forward PEG ratio of 1.77 indicates reasonable valuation for growth. Analysts expect EPS to grow +1.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $78.80, with bear and bull scenarios of $49.64 and $103.82 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
KLICKulicke and Soffa Industries, Inc. | $6.4B | $121.87 | $70.00 | -42.6% | Buy | 35.7x | 11 |
VICRVicor Corporation | $14.9B | $331.37 | $297.50 | -10.2% | Buy | 111.5x | 7 |
INTTinTEST Corporation | $235M | $18.80 | $11.33 | -39.7% | Buy | 40.3x | 5 |
PLXSPlexus Corp. | $8.0B | $299.97 | $265.00 | -11.7% | Buy | 36.6x | 18 |
AVXAvax One Technology Ltd | $45M | $5.57 | — | — | — | — | — |
MLABMesa Laboratories, Inc. | $525M | $95.10 | $94.00 | -1.2% | Hold | 10.5x | 8 |
NOVTNovanta Inc. | $5.5B | $155.30 | $180.00 | +15.9% | Buy | 43.3x | 3 |
OSISOSI Systems, Inc. | $3.7B | $222.78 | $310.00 | +39.2% | Buy | 21.4x | 18 |
GRMNGarmin Ltd. | $45.2B | $234.20 | $270.67 | +15.6% | Hold | 24.3x | 28 |
MCHPMicrochip Technology Incorporated | $54.0B | $99.77 | $107.82 | +8.1% | Buy | 63.6x | 46 |
Quick answers to the most common questions about buying CTS stock.
The consensus price target for CTS is $N/A, close to the current price of $67 (N/A% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
CTS has a consensus rating of "Hold" based on 4 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
CTS trades at a forward P/E of 27.572x, representing a moderate valuation. With analysts targeting $N/A (N/A% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $N/A for CTS, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $104 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CTS is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CTS stock forecast based on 4 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $79, with bear/bull scenarios of $50/$104.
Our quantitative valuation model calculates CTS's fair value at $79 (base case), with a bear case of $50 and bull case of $104. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
CTS trades at a forward P/E ratio of 27.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 30.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
CTS appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CTS analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $50-$104 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.